PL3494133T3 - Receptory limfocytów t anty-kras-g12d - Google Patents

Receptory limfocytów t anty-kras-g12d

Info

Publication number: PL3494133T3
Authority: PL; Poland
Prior art keywords: kras; cell receptors; receptors; cell
Prior art date: 2016-08-02

Application number

PL17749580.1T

Other languages

English (en)

Inventor

Eric TRAN

Yong-Chen LU

Paul F. Robbins

Steven A. Rosenberg

Zhili ZHENG

Original Assignee

The U.S.A. As Represented By The Secretary, Department Of Health And Human Services

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-08-02

Filing date

2017-07-31

Publication date

2022-11-21

2017-07-31 Application filed by The U.S.A. As Represented By The Secretary, Department Of Health And Human Services filed Critical The U.S.A. As Represented By The Secretary, Department Of Health And Human Services

2022-11-21 Publication of PL3494133T3 publication Critical patent/PL3494133T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Plant Pathology (AREA)
Epidemiology (AREA)

PL17749580.1T 2016-08-02 2017-07-31 Receptory limfocytów t anty-kras-g12d PL3494133T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662369883P	2016-08-02	2016-08-02
PCT/US2017/044615 WO2018026691A1 (en)	2016-08-02	2017-07-31	Anti-kras-g12d t cell receptors

Publications (1)

Publication Number	Publication Date
PL3494133T3 true PL3494133T3 (pl)	2022-11-21

Family

ID=59564253

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL17749580.1T PL3494133T3 (pl)	2016-08-02	2017-07-31	Receptory limfocytów t anty-kras-g12d

Country Status (20)

Country	Link
US (6)	US10611816B2 (pl)
EP (2)	EP4159751A1 (pl)
JP (4)	JP6993402B2 (pl)
KR (1)	KR102527052B1 (pl)
CN (2)	CN109790211B (pl)
AU (3)	AU2017306038B2 (pl)
CY (1)	CY1125601T1 (pl)
DK (1)	DK3494133T3 (pl)
ES (1)	ES2928051T3 (pl)
HR (1)	HRP20221183T1 (pl)
HU (1)	HUE060121T2 (pl)
IL (2)	IL301894B2 (pl)
LT (1)	LT3494133T (pl)
PL (1)	PL3494133T3 (pl)
PT (1)	PT3494133T (pl)
RS (1)	RS63615B1 (pl)
SG (2)	SG10201913959WA (pl)
SI (1)	SI3494133T1 (pl)
SM (1)	SMT202200379T1 (pl)
WO (1)	WO2018026691A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4159751A1 (en) *	2016-08-02	2023-04-05	The United States of America, as represented by the Secretary, Department of Health and Human Services	Anti-kras-g12d t cell receptors
GB201700621D0 (en)	2017-01-13	2017-03-01	Guest Ryan Dominic	Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
MX2020003117A (es)	2017-09-20	2020-08-20	Us Health	Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
CA3077595A1 (en)	2017-10-05	2019-04-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods for diagnosing, monitoring and treating neurological diseases and disorders
WO2019246286A1 (en)	2018-06-19	2019-12-26	Neon Therapeutics, Inc.	Neoantigens and uses thereof
CA3127673A1 (en)	2019-01-25	2020-07-30	The Trustees Of The University Of Pennsylvania	Compositions and methods for targeting mutant ras
GB2596461B (en) *	2019-02-20	2023-09-27	Fred Hutchinson Cancer Center	Binding proteins specific for RAS neoantigens and uses thereof
CN110172089B (zh) *	2019-06-11	2020-01-07	北京鼎成肽源生物技术有限公司	一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) *	2019-06-19	2020-12-22	上海交通大学医学院	肿瘤新抗原多肽及其用途
CN112760290A (zh) *	2019-10-21	2021-05-07	郑州大学	携带突变的肿瘤驱动基因的干细胞及其用途
CN112759641B (zh) *	2019-11-01	2023-01-20	香雪生命科学技术（广东）有限公司	一种识别Kras G12V的高亲和力TCR
US20220409711A1 (en) *	2019-11-05	2022-12-29	Board Of Regents, The University Of Texas System	Hla restricted hormad1 t cell receptors and uses thereof
KR20220119439A (ko)	2019-12-20	2022-08-29	인스틸 바이오 유케이 리미티드	종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도
JP7614659B2 (ja) *	2019-12-30	2025-01-16	ブリスターイムノテックリミテッド	強化されたｔ細胞受容体ｓｔａｒ及びその用途
JP7591772B2 (ja) *	2020-05-25	2024-11-29	ブリスターイムノテックリミテッド	強化された合成ｔ細胞受容体及び抗原受容体
US20230272038A1 (en) *	2020-07-13	2023-08-31	The United States Of America,As Represented By The Secretary,Department Of Health And Human Services	Hla class ii-restricted drb t cell receptors against ras with g12d mutation
WO2022072760A1 (en) *	2020-10-02	2022-04-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Hla class ii-restricted dq t cell receptors against ras with g13d mutation
EP4247401A4 (en) *	2020-11-20	2025-06-11	Think Therapeutics, Inc.	COMPOSITIONS AND METHODS FOR OPTIMIZED PEPTIDE VACCINES
AU2021388167A1 (en) *	2020-11-25	2023-07-06	Geneius Biotechnology, Inc.	Antigen specific t cells and methods of making and using same
IL305393A (en)	2021-02-25	2023-10-01	Alaunos Therapeutics Inc	Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
BR112023022765A2 (pt)	2021-05-05	2024-01-02	Immatics Biotechnologies Gmbh	Proteínas de ligação ao antígeno que ligam especificamente o prame
US20250145950A1 (en)	2022-02-01	2025-05-08	Alaunos Therapeutics, Inc.	Methods for Activation and Expansion of T Cells
CN114920823B (zh) *	2022-05-27	2023-10-17	重庆医科大学	Tcr或其抗原结合片段及其应用
WO2024020537A2 (en) *	2022-07-22	2024-01-25	Board Of Regents, The University Of Texas System	Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy
CN115850444B (zh) *	2022-09-15	2025-01-28	重庆医科大学	Tcr或其抗原结合片段及其应用
CN117777270B (zh) *	2022-09-29	2025-04-25	广州医科大学	一种t细胞受体(tcr)及其用途
CN120693174A (zh) *	2022-12-13	2025-09-23	百欧恩泰美国公司	T细胞受体构建体及其用途
WO2025006196A1 (en)	2023-06-28	2025-01-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	T cell receptors targeting ras with g12d, g12r, or g12v mutation
CN120157754A (zh) *	2023-12-14	2025-06-17	新景智源生物科技(苏州)有限公司	Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
WO2025259799A2 (en) *	2024-06-12	2025-12-18	Biontech Us Inc.	T cell receptor compositions and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5776459A (en) *	1989-07-19	1998-07-07	Connetics Corporation	TCR V beta 5 peptides
US20020150891A1 (en) *	1994-09-19	2002-10-17	Leroy E. Hood	Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region
US7709002B1 (en)	1996-04-19	2010-05-04	The United States Of America As Represented By The Department Of Health And Human Services	Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en)	1997-08-27	1999-03-03	Norsk Hydro As	Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
US8034334B2 (en)	2002-09-06	2011-10-11	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
AU2008206442B2 (en)	2007-01-12	2012-10-18	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	gp100-specific T cell receptors and related materials and methods of use
US8383099B2 (en)	2009-08-28	2013-02-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Adoptive cell therapy with young T cells
AU2011304728A1 (en)	2010-09-20	2013-03-14	Biontech Ag	Antigen-specific T cell receptors and T cell epitopes
US20120244133A1 (en)	2011-03-22	2012-09-27	The United States of America, as represented by the Secretary, Department of Health and	Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CA3114877C (en)	2011-09-15	2023-09-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
KR20140100938A (ko) *	2011-11-30	2014-08-18	도쿠리츠교세이호진 고쿠리츠간켄큐센터	유도 악성 줄기세포
CN105658206A (zh) *	2013-06-03	2016-06-08	诺华股份有限公司	抗pd-l1抗体与mek抑制剂和/或braf抑制剂的组合
GB201313377D0 (en) *	2013-07-26	2013-09-11	Adaptimmune Ltd	T cell receptors
GB201314404D0 (en)	2013-08-12	2013-09-25	Immunocore Ltd	T Cell Receptors
ES2784261T3 (es)	2014-11-26	2020-09-23	Us Health	Receptores de células T anti-KRAS mutado
ES2879287T3 (es)	2015-09-15	2021-11-22	Us Health	Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8
EP4159751A1 (en) *	2016-08-02	2023-04-05	The United States of America, as represented by the Secretary, Department of Health and Human Services	Anti-kras-g12d t cell receptors
WO2025006196A1 (en)	2023-06-28	2025-01-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	T cell receptors targeting ras with g12d, g12r, or g12v mutation

2017
- 2017-07-31 EP EP22182473.3A patent/EP4159751A1/en active Pending
- 2017-07-31 IL IL301894A patent/IL301894B2/en unknown
- 2017-07-31 HU HUE17749580A patent/HUE060121T2/hu unknown
- 2017-07-31 PL PL17749580.1T patent/PL3494133T3/pl unknown
- 2017-07-31 ES ES17749580T patent/ES2928051T3/es active Active
- 2017-07-31 DK DK17749580.1T patent/DK3494133T3/da active
- 2017-07-31 WO PCT/US2017/044615 patent/WO2018026691A1/en not_active Ceased
- 2017-07-31 RS RS20220894A patent/RS63615B1/sr unknown
- 2017-07-31 SI SI201731231T patent/SI3494133T1/sl unknown
- 2017-07-31 IL IL264425A patent/IL264425B2/en unknown
- 2017-07-31 SM SM20220379T patent/SMT202200379T1/it unknown
- 2017-07-31 LT LTEPPCT/US2017/044615T patent/LT3494133T/lt unknown
- 2017-07-31 CN CN201780059356.4A patent/CN109790211B/zh active Active
- 2017-07-31 HR HRP20221183TT patent/HRP20221183T1/hr unknown
- 2017-07-31 SG SG10201913959WA patent/SG10201913959WA/en unknown
- 2017-07-31 CN CN202410214235.4A patent/CN118063591A/zh active Pending
- 2017-07-31 EP EP17749580.1A patent/EP3494133B1/en active Active
- 2017-07-31 SG SG11201900654QA patent/SG11201900654QA/en unknown
- 2017-07-31 PT PT177495801T patent/PT3494133T/pt unknown
- 2017-07-31 US US16/321,899 patent/US10611816B2/en active Active
- 2017-07-31 AU AU2017306038A patent/AU2017306038B2/en active Active
- 2017-07-31 KR KR1020197005837A patent/KR102527052B1/ko active Active
- 2017-07-31 JP JP2019505220A patent/JP6993402B2/ja active Active
2020
- 2020-04-02 US US16/838,395 patent/US11208456B2/en active Active
2021
- 2021-06-11 US US17/345,390 patent/US11897933B2/en active Active
- 2021-12-03 US US17/541,619 patent/US11840561B2/en active Active
- 2021-12-09 JP JP2021199878A patent/JP7413338B2/ja active Active
2022
- 2022-09-29 CY CY20221100645T patent/CY1125601T1/el unknown
2023
- 2023-09-21 AU AU2023233125A patent/AU2023233125B2/en active Active
- 2023-12-27 JP JP2023221526A patent/JP7649370B2/ja active Active
2024
- 2024-01-25 US US18/423,020 patent/US12391742B2/en active Active
2025
- 2025-03-07 JP JP2025036871A patent/JP2025090690A/ja active Pending
- 2025-07-15 US US19/269,450 patent/US20250340611A1/en active Pending
2026
- 2026-01-15 AU AU2026200276A patent/AU2026200276A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2017306038A1 (en)	2019-02-14
IL301894B2 (en)	2025-02-01
JP7649370B2 (ja)	2025-03-19
US20220089677A1 (en)	2022-03-24
IL264425B1 (en)	2023-05-01
JP2024045139A (ja)	2024-04-02
US11208456B2 (en)	2021-12-28
EP3494133A1 (en)	2019-06-12
JP6993402B2 (ja)	2022-02-03
US11897933B2 (en)	2024-02-13
AU2023233125B2 (en)	2025-10-16
WO2018026691A1 (en)	2018-02-08
JP7413338B2 (ja)	2024-01-15
IL264425A (pl)	2019-03-31
EP3494133B1 (en)	2022-07-06
ES2928051T3 (es)	2022-11-15
US20250340611A1 (en)	2025-11-06
PT3494133T (pt)	2022-09-28
US10611816B2 (en)	2020-04-07
KR102527052B1 (ko)	2023-04-27
SI3494133T1 (sl)	2022-11-30
KR20190064566A (ko)	2019-06-10
US11840561B2 (en)	2023-12-12
AU2023233125A1 (en)	2023-10-12
DK3494133T3 (da)	2022-09-19
US20190177395A1 (en)	2019-06-13
LT3494133T (lt)	2022-12-12
AU2017306038B2 (en)	2023-06-22
CA3032870A1 (en)	2018-02-08
EP4159751A1 (en)	2023-04-05
HRP20221183T1 (hr)	2022-12-09
IL264425B2 (en)	2023-09-01
US12391742B2 (en)	2025-08-19
CN109790211A (zh)	2019-05-21
CY1125601T1 (el)	2026-02-25
JP2022050400A (ja)	2022-03-30
SG10201913959WA (en)	2020-03-30
CN118063591A (zh)	2024-05-24
US20210300988A1 (en)	2021-09-30
IL301894A (en)	2023-06-01
SG11201900654QA (en)	2019-02-27
RS63615B1 (sr)	2022-10-31
US20240209059A1 (en)	2024-06-27
SMT202200379T1 (it)	2022-11-18
CN109790211B (zh)	2024-03-26
JP2019527555A (ja)	2019-10-03
IL301894B1 (en)	2024-10-01
US20200247869A1 (en)	2020-08-06
HUE060121T2 (hu)	2023-01-28
JP2025090690A (ja)	2025-06-17
AU2026200276A1 (en)	2026-02-19

Publication	Publication Date	Title
DK3440106T3 (da)	2021-10-04	T-cellereceptorer
DK3440105T3 (da)	2022-06-13	T-cellereceptorer
DK3494133T3 (da)	2022-09-19	Anti-kras-g12d-t-cellereceptorer
IL262124A (en)	2018-11-29	T cell receptors
IL262146A (en)	2018-11-29	T cell receptors
PT3223850T (pt)	2020-04-13	Receptores de células t anti-kras mutado
DK3305266T3 (da)	2020-08-17	Stiftformig stimulationsindretning
EP4015404C0 (en)	2023-12-13	STRAPPING DEVICE
DK3404169T3 (da)	2021-04-26	Gondolanordning
DK3448882T3 (da)	2022-02-21	Anti-kk-lc-1-t-cellereceptorer
DK3394094T3 (da)	2022-07-04	T-celle receptorer specifikke for ny-eso-1 tumor antigen-hla-a*02 komplekset
EP3472208C0 (en)	2023-06-07	T cell receptors and uses thereof
IL249313A0 (en)	2017-02-28	Improved t cell compositions
DK3514172T3 (da)	2020-04-06	Claudin-6-specifikke immunoreceptorer og t-celleepitoper
DK4011339T3 (da)	2024-05-06	Stomianordning
DK3426850T3 (da)	2020-01-13	Kabellægnings-indretning
EP3529267C0 (en)	2023-07-26	T CELL RECEPTOR
LT3433270T (lt)	2023-10-25	T ląstelių receptoriai
DK3290073T3 (da)	2021-02-15	Forbindelsesanordning
EP3551657A4 (en)	2020-07-15	CHIMERIC CHLOROTOXIN RECEPTORS
EP3453648C0 (de)	2024-04-03	Zulaufvorrichtung
DK3516155T3 (da)	2024-09-30	Forbindelsesanordning
ITUA20161802A1 (it)	2017-09-18	Dispositivo reggipensile
IL264855B1 (en)	2023-05-01	T cell receptors and immune therapy using the same
DK3504072T3 (da)	2020-11-09	Sammenkoblingsindretning